An Exploratory Phase 1 Study to Assess the Tolerability, Pharmacokinetics and Clinical Activity of ON 01910.Na Concentrate Administered Orally as Escalating Single and Multiple Doses Twice a Day up to 14 Days of a 21-Days Cycle in Patients with Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2016
At a glance
- Drugs Rigosertib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Onconova Therapeutics
- 21 Mar 2012 Additional lead trial investigator identified as reported by Clinical Trials Registry - India.
- 21 Mar 2012 Actual end date (Apr 2012) added as reported by Clinical Trials Registry - India.
- 21 Mar 2012 Status changed from recruiting to completed as reported by Clinical Trials Registry - India.